All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Completed, but no date | 2004-002176-42 | Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecol... | bad-data | |
Reported results | 2005-001300-39 | A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep... | 2008-06-19 | due-trials |
Reported results | 2010-019424-31 | A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type... | 2013-04-30 | due-trials |
Reported results Terminated | 2011-000756-42 | A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. Pilotstudie der Phase 2, multize... | 2012-07-11 | due-trials |
Reported results | 2011-006201-10 | A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation | 2016-12-09 | due-trials |
Exempt, with results | 2012-002527-15 | Study Brand Name : REPARO Study full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the... | 2016-05-19 | not-yet-due |
Reported results | 2013-002244-86 | Effect of reparixin on long-term outcomes after pancreatic islet transplantation in type 1 diabetes mellitus patients. A non-interventional, monocentre study to extend up to 3 years the follow-up of p... | 2015-06-23 | due-trials |
Reported results | 2013-004271-12 | An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye Eine offene Studie zur Evaluierung der Sich... | 2015-01-30 | due-trials |
Reported results | 2014-003968-20 | A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes | 2019-05-15 | due-trials |
Reported results | 2014-004796-23 | A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer... | 2020-03-23 | due-trials |
Reported results | 2016-002172-27 | A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Nerve... | 2017-09-04 | due-trials |
Completed, but no date, and reported results Terminated | 2019-002114-38 | Randomized, single dose, placebo-controlled, double-blind, parallel group study to evaluate the onset of pain response after administration of ketoprofen lysine salt 40 mg, in male and female subjects... | bad-data | |
Completed, but no date, and reported results Terminated | 2020-001645-40 | Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia Studio adattativo di fase 2/3,... | bad-data | |
Ongoing | 2020-001926-71 | A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low ... | not-yet-due | |
Listed as ongoing, but also has a completion date | 2020-002966-15 | A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserv... | 2023-10-11 | bad-data |
Not reported Terminated | 2020-003296-18 | Effect of oral ladarixin 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatric ... | 2023-04-21 | due-trials |
Ongoing, reported early | 2020-003936-25 | Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patients... | not-yet-due | |
Completed, but no date, and reported results | 2020-005919-51 | A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia. Studio m... | bad-data | |
Reported results Terminated | 2021-000382-32 | A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastatic ... | 2022-09-09 | due-trials |
Ongoing | 2021-001629-38 | A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain comp... | not-yet-due | |
Completed, but no date, and reported results Terminated | 2021-002476-39 | Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immun... | bad-data | |
Reported results | 2021-003346-21 | A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with sever... | 2022-12-16 | due-trials |
Ongoing, reported early | 2021-003749-39 | A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with seve... | not-yet-due | |
Ongoing | 2021-006951-32 | Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinatio... | not-yet-due | |
Completed, report not yet due Terminated | 2022-000743-68 | A phase II randomized, placebo-controlled, double-blinded, 2-parallel arm, clinical trial evaluating Ladarixin 400 mg twice a day as adjunctive therapy to improve glycemic control in overweight insuli... | 2023-09-18 | not-yet-due |
Ongoing | 2022-001612-25 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acu... | not-yet-due |